Sonnet BioTherapeutics 株価情報 (NASDAQ: SONN)

最新ニュース Sonnet BioTherapeutics (NASDAQ:SONN) 株価情報

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) reported quarterly earnings of $0.05 per share. This is a 600 percent increase over losses of $(0.01) per share from the same period last year. The company reported $17.63 million in sales this quarter. This is a 15.09 percent increase over sales of $15.32 million the same period last year.

Earnings

News

SLNG

Stabilis Solutions Q3 EPS $0.05 Up From $(0.01) YoY, Sales $17.63M Up From $15.32M YoY

Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) posted its third-quarter revenue of $331 million on Wednesday afternoon, marking a modest 1% year-over-year decline.
Gross profit reached $160.5 million, with a gross margin of 49%, a significant improvement of 312 basis points from the prior year. Gross margin measures the profitability of the core business (i.e., revenue minus the direct cost of goods sold). This indicates that for each dollar of sales, Curaleaf retained 49 cents after direct costs. However, gross margin doesn't account for other operating expenses.
CEO Boris Jordan<a href="https://www.prnewswire.com/news-releases/curaleaf-reports-third-quarter-2024-results-302297985.html"> noted</a> that Curaleaf's <a href="https://www.benzinga.com/markets/cannabis/24/10/41526491/cannabis-giant-reveals-uks-illegal-online-sales-have-grown-50-over-2-years-urges-government-to-a">international business</a>, which grew 82% year-over-year to $30 million, offers a strategic opportunity amidst U.S. market saturation.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Adjusted EBITDA Reflects Operational Discipline</h3>
The company reported a net loss of $44 million, equivalent to $0.07 per share, with adjusted EBITDA at $75.3 million, maintaining an adjusted EBITDA margin of 23%. 
Operating cash flow reached $42.3 million, contributing to a year-to-date free cash flow of $53 million. 
Jordan highlighted the company's "disciplined execution" amid <a href="https://www.benzinga.com/markets/cannabis/24/11/41782344/tilray-trulieve-and-other-cannabis-stocks-nosediving-as-industry-faces-new-wave-of-political-unc">challenging market conditions</a>.
<h3 class="wp-block-heading">Securing Financial Flexibility</h3>
Curaleaf recently obtained a $40 million revolving credit facility at a competitive 7.99% interest rate, a significant milestone for the cannabis industry. 
With $90 million in cash and a continued focus on capital efficiency, Curaleaf is positioned to navigate market pressures and further expand its footprint in both U.S. and international markets.
Price Action: At the close on Wednesday, Curaleaf&#8217;s stock was priced at $2.18 per share, reflecting a 30.26% drop.
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/11/41775004/gardening-giant-scotts-miracle-gro-reports-46-yoy-drop-in-q4-net-sales-for-its-cannabis-focused-"> Gardening Giant Scotts Miracle-Gro Reports 46% YoY Drop In Q4 Net Sales For Its Cannabis-Focused Subsidiary</a>

Cannabis

Markets

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Curaleaf Q3 Results: Strong Margins But $44M Loss, What's Next For Investors?

Management

EnerSys Says David Shaffer Notified His Intention To Retire As President And CEO Effective May 2025; Shawn O'Connell Named As Successor

Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.96) by 17.71 percent. This is a 43.04 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $274.638 million which beat the analyst consensus estimate of $270.747 million by 1.44 percent. This is a 1.05 percent decrease over sales of $277.560 million the same period last year.

Earnings Beats

Earnings Misses

RRGB

Red Robin Gourmet Burgers Q3 2024 Adj. EPS $(1.13) Misses $(0.96) Estimate, Sales $274.638M Beat $270.747M Estimate

COST

Costco Earlier Reported Net Sales Of $20.03B For The Retail Month Of Oct., Up 7.2% YoY

Epsilon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSN#NASDAQ">EPSN</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.04 by 50 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.29 million which beat the analyst consensus estimate of $6.90 million by 5.62 percent. This is a 15.48 percent increase over sales of $6.31 million the same period last year.

EPSN

Epsilon Energy Q3 EPS $0.02 Misses $0.04 Estimate, Sales $7.29M Beat $6.90M Estimate

Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.95 by 8.42 percent. The company reported quarterly sales of $665.915 million which missed the analyst consensus estimate of $666.619 million by 0.11 percent. This is a 1.61 percent decrease over sales of $676.808 million the same period last year.

VSTO

Vista Outdoor Q2 2025 Adj. EPS $1.03 Beats $0.95 Estimate, Sales $665.915M Miss $666.619M Estimate

Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.78 percent. This is a 12.7 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $2.250 million which beat the analyst consensus estimate of $2.100 million by 7.14 percent. This is a 177.78 percent increase over sales of $810.000 thousand the same period last year.

AEVA

Aeva Technologies Q3 2024 Adj. EPS $(0.55) Beats $(0.59) Estimate, Sales $2.250M Beat $2.100M Estimate

CrossAmerica Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAPL#NYSE">CAPL</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.25 by 8 percent. The company reported quarterly sales of $1.079 billion which missed the analyst consensus estimate of $1.284 billion by 15.95 percent. This is a 10.83 percent decrease over sales of $1.210 billion the same period last year.

CAPL

CrossAmerica Partners Q3 2024 GAAP EPS $0.27 Beats $0.25 Estimate, Sales $1.079B Miss $1.284B Estimate

EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.13 by 123.08 percent. This is a 130 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $1.61 billion which missed the analyst consensus estimate of $1.74 billion by 7.56 percent. This is a 7.88 percent decrease over sales of $1.75 billion the same period last year.

ENLC

EnLink Midstream Q3 EPS $(0.03) Misses $0.13 Estimate, Sales $1.61B Miss $1.74B Estimate

Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) reported quarterly earnings of $1.49 per share which missed the analyst consensus estimate of $1.57 by 5.1 percent. The company reported quarterly sales of $102.339 million which missed the analyst consensus estimate of $103.638 million by 1.25 percent. This is a 5.50 percent decrease over sales of $108.294 million the same period last year.

REPX

Riley Exploration Permian Q3 2024 Adj. EPS $1.49 Misses $1.57 Estimate, Sales $102.339M Miss $103.638M Estimate

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are ripping higher in Wednesday&#8217;s after-hours session on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/b41786448/applovin-announces-third-quarter-2024-financial-results">rundown of the report</a>.
<ul>
<li>Q3 Revenue: $1.2 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.13 billion</li>
</ul>
<ul>
<li>Q3 EPS: $1.25, versus estimates of 94 cents</li>
</ul>
Total revenue was up 39% year-over-year. Software platform revenue increased 66% year-over-year, while Apps revenue grew 1%. Cash flow from operations was $551 million in the quarter and free cash flow came in at $545 million. Applovin ended the quarter with $568 million in cash and cash equivalents. 
Applovin&#8217;s board increased the company&#8217;s share repurchase program by $2 billion. The company said it now has $2.3 billion remaining under the buyback. The company expects to fund future repurchases with free cash flow.
&#8220;We had another fantastic quarter in the third quarter. Our AXON models continue to improve through self-learning and, more importantly this quarter, from technology enhancements by our engineering team. As we continue to improve our models our advertising partners are able to successfully spend at a greater scale,&#8221; the company said in a letter to shareholders.
Outlook: Applovin expects fourth-quarter revenue to be in the range of $1.24 billion to $1.26 billion. The company expects fourth-quarter adjusted EBITDA to be in the range of $740 million to $760 million.
Management is currently discussing the quarter on a conference call that kicked off at 5 p.m. ET.
APP Price Action: <a href="http://benzinga.com/quote/app">Applovin shares</a> were up 28.15% after hours at $216 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/11/41789162/lyft-stock-drives-higher-after-better-than-expected-q3-results">Lyft Stock Drives Higher After Better-Than-Expected Q3 Results</a>
Photo: Pixabay.

Guidance

After-Hours Center

Movers

Applovin Stock Soars After Q3 Earnings Report: Revenue Beat, EPS Beat, Strong Software Platform Growth

Biotech

General

CPIX

Cumberland Pharmaceuticals Receives FDA Orphan Drug, Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 50 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $9.208 million which beat the analyst consensus estimate of $8.110 million by 13.53 percent. This is a 81.26 percent increase over sales of $5.080 million the same period last year.

Myomo Q3 2024 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $9.208M Beat $8.110M Estimate

ARDT

Ardent Health Raises FY24 Revenue To $5.8B-$5.875B From $5.75B-$5.9B; Updates Diluted EPS To $1.18-$1.32 From $1.23-$1.37

SENEA

Seneca Foods Q2 Revenue $425.5M Up From $407.5M YoY

Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.10) by 140 percent. This is a 284.62 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $75.687 million which missed the analyst consensus estimate of $78.918 million by 4.09 percent. This is a 5.79 percent increase over sales of $71.543 million the same period last year.

Full House Resorts Q3 2024 GAAP EPS $(0.24) Misses $(0.10) Estimate, Sales $75.687M Miss $78.918M Estimate

Select Medical Holdings Corporation Declares Special Stock Distribution To Spin-Off Concentra; Estimates Stockholders Will Receive Approximately 0.806971 Shares Of Concentra's Common Stock For Every Share Of Select Medical's Common Stock Held As Of The Close Of Business On The Record Date

Algoma Steel Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.27) by 166.67 percent. This is a 500 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $440.03 million which missed the analyst consensus estimate of $568.90 million by 22.65 percent. This is a 19.42 percent decrease over sales of $546.10 million the same period last year.

ASTL

Algoma Steel Gr Q2 EPS $(0.72) Misses $(0.27) Estimate, Sales $440.03M Miss $568.90M Estimate

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.175 million which missed the analyst consensus estimate of $34.645 million by 1.36 percent. This is a 3.70 percent decrease over sales of $35.487 million the same period last year.

GMRE

Global Medical REIT Q3 2024 FFO $0.22 Beats $0.20 Estimate, Sales $34.175M Miss $34.645M Estimate

Warning: SONN is at high risk of performing badly

Sonnet BioTherapeutics (SONN) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,134,635 entitled "...

Sonnet BioTherapeutics announces USPTO issued U.S. patent on IL-18

The latest announcement is out from Sonnet BioTherapeutics Holdings ( ($SONN) ). Sonnet BioTherapeutics has secured a U.S. patent for two innovativ...

Sonnet BioTherapeutics Secures Patent for Cancer Drugs

Sonnet BioTherapeutics (SONN) Holdings announced the pricing of an underwritten public offering of 1.11M shares of common stock and common warrants...

Sonnet BioTherapeutics prices $5M at-the-market offering

SONN

Contracts

Press Releases

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Comments

Sonnet BioTherapeutics

ニュース

最新ニュース Sonnet BioTherapeutics (NASDAQ:SONN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル